Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma

Phase 3

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 450

Registration Number: NCT00028886

Locations: 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱
Isala Klinieken - locatie Sophia, Zwolle, Netherlands
🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands

and more 14 locations

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 400

Registration Number: NCT00028717

Locations: 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱
Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands

and more 10 locations

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025649

Locations: 🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇫🇷
Centre Hospitalier Regional de Purpan, Toulouse, France
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway

and more 8 locations

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025610

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium

and more 9 locations

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 450

Registration Number: NCT00003013

Locations: 🇦🇹
Kaiser Franz Josef Hospital, Vienna, Austria
🇨🇿
Radiotherapy Institute, Ostrava-Poruba, Czech Republic
🇸🇰
St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia

and more 25 locations

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025623

Locations: 🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇫🇷
Centre Hospitalier Regional de Purpan, Toulouse, France

and more 8 locations

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Phase 3

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: EBMT Solid Tumors Working Party

Registration Number: NCT00004921

Locations: 🇩🇪
Klinikum Nuernberg - Klinikum Nord, Nuernberg, Germany
🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇦🇹
Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria

and more 14 locations

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: German Low Grade Lymphoma Study Group

Registration Number: NCT00016887

Locations: 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇮🇹
Ospedale Civile Alessandria, Alessandria, Italy

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025597

Locations: 🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇬🇧
Bristol Royal Hospital for Children, Bristol, England, United Kingdom

and more 8 locations

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin

First Posted Date: 2003-01-27

Last Posted Date: 2024-03-21

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 5351

Registration Number: NCT00003782

Locations: 🇺🇸
Creticos Cancer Center at Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States
🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
CCOP - Virginia Mason Research Center, Seattle, Washington, United States

and more 154 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy